Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.

Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME.

Nat Med. 2018 Aug 9. doi: 10.1038/s41591-018-0169-5. [Epub ahead of print]

PMID:
30093731
2.

Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.

Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME.

Nat Med. 2018 Jul;24(7):1070-1080. doi: 10.1038/s41591-018-0061-3. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Aug 9;:.

PMID:
29942096
3.

The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.

Bricambert J, Alves-Guerra MC, Esteves P, Prip-Buus C, Bertrand-Michel J, Guillou H, Chang CJ, Vander Wal MN, Canonne-Hergaux F, Mathurin P, Raverdy V, Pattou F, Girard J, Postic C, Dentin R.

Nat Commun. 2018 May 29;9(1):2092. doi: 10.1038/s41467-018-04361-y.

4.

Increased Hepatic PDGF-AA Signaling Mediates Liver Insulin Resistance in Obesity-Associated Type 2 Diabetes.

Abderrahmani A, Yengo L, Caiazzo R, Canouil M, Cauchi S, Raverdy V, Plaisance V, Pawlowski V, Lobbens S, Maillet J, Rolland L, Boutry R, Queniat G, Kwapich M, Tenenbaum M, Bricambert J, Saussenthaler S, Anthony E, Jha P, Derop J, Sand O, Rabearivelo I, Leloire A, Pigeyre M, Daujat-Chavanieu M, Gerbal-Chaloin S, Dayeh T, Lassailly G, Mathurin P, Staels B, Auwerx J, Schürmann A, Postic C, Schafmayer C, Hampe J, Bonnefond A, Pattou F, Froguel P.

Diabetes. 2018 Jul;67(7):1310-1321. doi: 10.2337/db17-1539. Epub 2018 May 4.

5.

MondoA Is an Essential Glucose-Responsive Transcription Factor in Human Pancreatic β-Cells.

Richards P, Rachdi L, Oshima M, Marchetti P, Bugliani M, Armanet M, Postic C, Guilmeau S, Scharfmann R.

Diabetes. 2018 Mar;67(3):461-472. doi: 10.2337/db17-0595. Epub 2017 Dec 27.

6.

A new pathway to eSCAPe lipotoxicity.

Benhamed F, Postic C.

Clin Res Hepatol Gastroenterol. 2018 Feb;42(1):3-5. doi: 10.1016/j.clinre.2017.10.005. Epub 2017 Nov 22.

PMID:
29174379
7.

Liver Reptin/RUVBL2 controls glucose and lipid metabolism with opposite actions on mTORC1 and mTORC2 signalling.

Javary J, Allain-Courtois N, Saucisse N, Costet P, Heraud C, Benhamed F, Pierre R, Bure C, Pallares-Lupon N, Do Cruzeiro M, Postic C, Cota D, Dubus P, Rosenbaum J, Benhamouche-Trouillet S.

Gut. 2017 Oct 26. pii: gutjnl-2017-314208. doi: 10.1136/gutjnl-2017-314208. [Epub ahead of print]

PMID:
29074727
8.

A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response.

Iroz A, Montagner A, Benhamed F, Levavasseur F, Polizzi A, Anthony E, Régnier M, Fouché E, Lukowicz C, Cauzac M, Tournier E, Do-Cruzeiro M, Daujat-Chavanieu M, Gerbal-Chalouin S, Fauveau V, Marmier S, Burnol AF, Guilmeau S, Lippi Y, Girard J, Wahli W, Dentin R, Guillou H, Postic C.

Cell Rep. 2017 Oct 10;21(2):403-416. doi: 10.1016/j.celrep.2017.09.065.

9.

Insights into the role of hepatocyte PPARα activity in response to fasting.

Régnier M, Polizzi A, Lippi Y, Fouché E, Michel G, Lukowicz C, Smati S, Marrot A, Lasserre F, Naylies C, Batut A, Viars F, Bertrand-Michel J, Postic C, Loiseau N, Wahli W, Guillou H, Montagner A.

Mol Cell Endocrinol. 2018 Aug 15;471:75-88. doi: 10.1016/j.mce.2017.07.035. Epub 2017 Jul 31.

PMID:
28774777
10.

Sweet Sixteenth for ChREBP: Established Roles and Future Goals.

Abdul-Wahed A, Guilmeau S, Postic C.

Cell Metab. 2017 Aug 1;26(2):324-341. doi: 10.1016/j.cmet.2017.07.004. Review.

11.

Dietary oleic acid regulates hepatic lipogenesis through a liver X receptor-dependent signaling.

Ducheix S, Montagner A, Polizzi A, Lasserre F, Régnier M, Marmugi A, Benhamed F, Bertrand-Michel J, Mselli-Lakhal L, Loiseau N, Martin PG, Lobaccaro JM, Ferrier L, Postic C, Guillou H.

PLoS One. 2017 Jul 21;12(7):e0181393. doi: 10.1371/journal.pone.0181393. eCollection 2017.

12.

MondoA/ChREBP: The usual suspects of transcriptional glucose sensing; Implication in pathophysiology.

Richards P, Ourabah S, Montagne J, Burnol AF, Postic C, Guilmeau S.

Metabolism. 2017 May;70:133-151. doi: 10.1016/j.metabol.2017.01.033. Epub 2017 Feb 4. Review.

PMID:
28403938
13.

Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.

Morzyglod L, Caüzac M, Popineau L, Denechaud PD, Fajas L, Ragazzon B, Fauveau V, Planchais J, Vasseur-Cognet M, Fartoux L, Scatton O, Rosmorduc O, Guilmeau S, Postic C, Desdouets C, Desbois-Mouthon C, Burnol AF.

Hepatology. 2017 Apr;65(4):1352-1368. doi: 10.1002/hep.28972. Epub 2017 Feb 21.

PMID:
27981611
14.

Emerging role of miR-21 in non-alcoholic fatty liver disease.

Benhamouche-Trouillet S, Postic C.

Gut. 2016 Nov;65(11):1781-1783. doi: 10.1136/gutjnl-2015-310044. Epub 2016 Jul 19. No abstract available.

PMID:
27436271
15.

Corrigendum: Matrix metalloproteinase 11 protects from diabesity and promotes metabolic switch.

Dali-Youcef N, Hnia K, Blaise S, Messaddeq N, Blanc S, Postic C, Valet P, Tomasetto C, Rio MC.

Sci Rep. 2016 May 31;6:26916. doi: 10.1038/srep26916. No abstract available.

16.

Novel Grb14-Mediated Cross Talk between Insulin and p62/Nrf2 Pathways Regulates Liver Lipogenesis and Selective Insulin Resistance.

Popineau L, Morzyglod L, Carré N, Caüzac M, Bossard P, Prip-Buus C, Lenoir V, Ragazzon B, Fauveau V, Robert L, Guilmeau S, Postic C, Komatsu M, Canonne-Hergaux F, Guillou H, Burnol AF.

Mol Cell Biol. 2016 Jul 29;36(16):2168-81. doi: 10.1128/MCB.00170-16. Print 2016 Aug 15.

17.

Matrix metalloproteinase 11 protects from diabesity and promotes metabolic switch.

Dali-Youcef N, Hnia K, Blaise S, Messaddeq N, Blanc S, Postic C, Valet P, Tomasetto C, Rio MC.

Sci Rep. 2016 Apr 29;6:25140. doi: 10.1038/srep25140. Erratum in: Sci Rep. 2016 May 31;6:26916.

18.

Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD.

Montagner A, Polizzi A, Fouché E, Ducheix S, Lippi Y, Lasserre F, Barquissau V, Régnier M, Lukowicz C, Benhamed F, Iroz A, Bertrand-Michel J, Al Saati T, Cano P, Mselli-Lakhal L, Mithieux G, Rajas F, Lagarrigue S, Pineau T, Loiseau N, Postic C, Langin D, Wahli W, Guillou H.

Gut. 2016 Jul;65(7):1202-14. doi: 10.1136/gutjnl-2015-310798. Epub 2016 Feb 1.

19.

Therapeutic potential of nicotinamide adenine dinucleotide for nonalcoholic fatty liver disease.

Gual P, Postic C.

Hepatology. 2016 Apr;63(4):1074-7. doi: 10.1002/hep.28383. Epub 2016 Feb 16. No abstract available.

PMID:
26661503
20.

Integration of ChREBP-Mediated Glucose Sensing into Whole Body Metabolism.

Baraille F, Planchais J, Dentin R, Guilmeau S, Postic C.

Physiology (Bethesda). 2015 Nov;30(6):428-37. doi: 10.1152/physiol.00016.2015. Review.

21.

Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth.

Schumacher Y, Aparicio T, Ourabah S, Baraille F, Martin A, Wind P, Dentin R, Postic C, Guilmeau S.

Oncogene. 2016 May 19;35(20):2602-14. doi: 10.1038/onc.2015.283. Epub 2015 Aug 24.

PMID:
26300003
22.

Hepatokines: unlocking the multi-organ network in metabolic diseases.

Iroz A, Couty JP, Postic C.

Diabetologia. 2015 Aug;58(8):1699-703. doi: 10.1007/s00125-015-3634-4. Epub 2015 Jun 2.

PMID:
26032022
23.

Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking.

Marmier S, Dentin R, Daujat-Chavanieu M, Guillou H, Bertrand-Michel J, Gerbal-Chaloin S, Girard J, Lotersztajn S, Postic C.

Hepatology. 2015 Oct;62(4):1086-100. doi: 10.1002/hep.27778. Epub 2015 May 6.

PMID:
25761756
24.

O-GlcNAcylation Links ChREBP and FXR to Glucose-Sensing.

Benhamed F, Filhoulaud G, Caron S, Lefebvre P, Staels B, Postic C.

Front Endocrinol (Lausanne). 2015 Jan 13;5:230. doi: 10.3389/fendo.2014.00230. eCollection 2014. Review.

25.

Gastric bypass surgery in NASH: a major modulator of hepatic mitochondrial dysfunction.

Baraille F, Guilmeau S, Postic C.

Gut. 2015 Apr;64(4):524-6. doi: 10.1136/gutjnl-2014-307738. Epub 2014 Jul 30. No abstract available.

PMID:
25080449
26.

Probabilistic assessment of exposure to nail cosmetics in French consumers.

Ficheux AS, Morisset T, Chevillotte G, Postic C, Roudot AC.

Food Chem Toxicol. 2014 Apr;66:36-43. doi: 10.1016/j.fct.2014.01.022. Epub 2014 Jan 19.

PMID:
24447976
27.

[The transcription factor ChREBP: a key modulator of insulin sensitivity?].

Benhamed F, Poupeau A, Postic C.

Med Sci (Paris). 2013 Aug-Sep;29(8-9):765-71. doi: 10.1051/medsci/2013298016. Epub 2013 Sep 5. Review. French.

28.

Novel insights into ChREBP regulation and function.

Filhoulaud G, Guilmeau S, Dentin R, Girard J, Postic C.

Trends Endocrinol Metab. 2013 May;24(5):257-68. doi: 10.1016/j.tem.2013.01.003. Epub 2013 Apr 15. Review.

PMID:
23597489
29.

Farnesoid X receptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes.

Caron S, Huaman Samanez C, Dehondt H, Ploton M, Briand O, Lien F, Dorchies E, Dumont J, Postic C, Cariou B, Lefebvre P, Staels B.

Mol Cell Biol. 2013 Jun;33(11):2202-11. doi: 10.1128/MCB.01004-12. Epub 2013 Mar 25.

30.

Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor.

Ducheix S, Montagner A, Polizzi A, Lasserre F, Marmugi A, Bertrand-Michel J, Podechard N, Al Saati T, Chétiveaux M, Baron S, Boué J, Dietrich G, Mselli-Lakhal L, Costet P, Lobaccaro JM, Pineau T, Theodorou V, Postic C, Martin PG, Guillou H.

J Hepatol. 2013 May;58(5):984-92. doi: 10.1016/j.jhep.2013.01.006. Epub 2013 Jan 16.

PMID:
23333450
31.

LRH-1-dependent glucose sensing determines intermediary metabolism in liver.

Oosterveer MH, Mataki C, Yamamoto H, Harach T, Moullan N, van Dijk TH, Ayuso E, Bosch F, Postic C, Groen AK, Auwerx J, Schoonjans K.

J Clin Invest. 2012 Aug;122(8):2817-26. doi: 10.1172/JCI62368. Epub 2012 Jul 9.

32.

Hidden variant of ChREBP in fat links lipogenesis to insulin sensitivity.

Dentin R, Langin D, Postic C.

Cell Metab. 2012 Jun 6;15(6):795-7. doi: 10.1016/j.cmet.2012.05.007.

33.

The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.

Benhamed F, Denechaud PD, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, Ratziu V, Serfaty L, Housset C, Capeau J, Girard J, Guillou H, Postic C.

J Clin Invest. 2012 Jun;122(6):2176-94. doi: 10.1172/JCI41636. Epub 2012 May 1.

34.

Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver.

Dentin R, Tomas-Cobos L, Foufelle F, Leopold J, Girard J, Postic C, Ferré P.

J Hepatol. 2012 Jan;56(1):199-209. doi: 10.1016/j.jhep.2011.07.019. Epub 2011 Aug 9.

PMID:
21835137
35.

O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver.

Guinez C, Filhoulaud G, Rayah-Benhamed F, Marmier S, Dubuquoy C, Dentin R, Moldes M, Burnol AF, Yang X, Lefebvre T, Girard J, Postic C.

Diabetes. 2011 May;60(5):1399-413. doi: 10.2337/db10-0452. Epub 2011 Apr 6.

36.

Cross-regulation of hepatic glucose metabolism via ChREBP and nuclear receptors.

Poupeau A, Postic C.

Biochim Biophys Acta. 2011 Aug;1812(8):995-1006. doi: 10.1016/j.bbadis.2011.03.015. Epub 2011 Mar 29. Review.

37.

Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes.

Dubuquoy C, Robichon C, Lasnier F, Langlois C, Dugail I, Foufelle F, Girard J, Burnol AF, Postic C, Moldes M.

J Hepatol. 2011 Jul;55(1):145-53. doi: 10.1016/j.jhep.2010.10.024. Epub 2010 Nov 30.

PMID:
21145868
38.

Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice.

Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R.

J Clin Invest. 2010 Dec;120(12):4316-31. doi: 10.1172/JCI41624. Epub 2010 Nov 15.

39.

Little caves ameliorate hepatic insulin signaling. Focus on "caveolin gene transfer improves glucose metabolism in diabetic mice".

Dugail I, Postic C.

Am J Physiol Cell Physiol. 2010 Mar;298(3):C442-5. doi: 10.1152/ajpcell.00542.2009. Epub 2009 Dec 23. No abstract available.

40.

Calpain activation is required for homocysteine-mediated hepatic degradation of inhibitor I kappa B alpha.

Hamelet J, Couty JP, Crain AM, Noll C, Postic C, Paul JL, Delabar JM, Viguier M, Janel N.

Mol Genet Metab. 2009 Jun;97(2):114-20. doi: 10.1016/j.ymgme.2009.02.005. Epub 2009 Feb 26.

PMID:
19299176
41.

The role of the lipogenic pathway in the development of hepatic steatosis.

Postic C, Girard J.

Diabetes Metab. 2008 Dec;34(6 Pt 2):643-8. doi: 10.1016/S1262-3636(08)74599-3. Review.

PMID:
19195625
42.

[Can the hyperactivity of lipogenesis cause hepatic steatosis? A role for ChREBP].

Robichon C, Girard J, Postic C.

Med Sci (Paris). 2008 Oct;24(10):841-6. doi: 10.1051/medsci/20082410841. Review. French.

43.

The transcription factor COUP-TFII is negatively regulated by insulin and glucose via Foxo1- and ChREBP-controlled pathways.

Perilhou A, Tourrel-Cuzin C, Kharroubi I, Henique C, Fauveau V, Kitamura T, Magnan C, Postic C, Prip-Buus C, Vasseur-Cognet M.

Mol Cell Biol. 2008 Nov;28(21):6568-79. doi: 10.1128/MCB.02211-07. Epub 2008 Sep 2.

44.
45.

Carbohydrate responsive element binding protein and lipid homeostasis.

Denechaud PD, Girard J, Postic C.

Curr Opin Lipidol. 2008 Jun;19(3):301-6. doi: 10.1097/MOL.0b013e3282ffafaa. Review.

PMID:
18460923
46.
47.

ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver.

Denechaud PD, Bossard P, Lobaccaro JM, Millatt L, Staels B, Girard J, Postic C.

J Clin Invest. 2008 Mar;118(3):956-64. doi: 10.1172/JCI34314.

48.

[The regulation of gene expression by glucose].

Girard J, Dentin R, Benhamed F, Denechaud PD, Postic C.

J Soc Biol. 2007;201(2):159-64. French.

PMID:
17978749
49.

Role of ChREBP in hepatic steatosis and insulin resistance.

Denechaud PD, Dentin R, Girard J, Postic C.

FEBS Lett. 2008 Jan 9;582(1):68-73. Epub 2007 Aug 14. Review.

50.

ChREBP, a transcriptional regulator of glucose and lipid metabolism.

Postic C, Dentin R, Denechaud PD, Girard J.

Annu Rev Nutr. 2007;27:179-92. Review.

PMID:
17428181

Supplemental Content

Loading ...
Support Center